ME
REGN icon

McIlrath & Eck’s Regeneron Pharmaceuticals REGN Stock Holding History

McIlrath & Eck’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-9
Closed -$7.39K – 929
2023
Q1 		$7.39K Buy
+9
New +$6.79K ﹤0.01% 598

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

McIlrath & Eck's REGN Position: Q2 2023 in Review

McIlrath & Eck sold out of Regeneron Pharmaceuticals (REGN) in Q2 2023, closing a stake of 9 shares — an estimated $7.39K sold.

McIlrath & Eck first reported a position in REGN in Q1 2023 and held it in 1 quarter. The position peaked at $7.39K in Q1 2023. 1,165 funds tracked by Wall St. Rank hold REGN as of Q2 2023.

  • McIlrath & Eck reported no remaining Regeneron Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • McIlrath & Eck sold 9 Regeneron Pharmaceuticals shares in Q2 2023, an estimated $7.39K.
  • McIlrath & Eck first reported a position in Regeneron Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • McIlrath & Eck's Regeneron Pharmaceuticals position peaked at $7.39K in Q1 2023.
  • 1,165 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2023.

Based on McIlrath & Eck's 13F filing for Q2 2023, filed 7 Aug 2023.